GeoVax Labs’ (GOVX) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a research note issued to investors on Friday morning,Benzinga reports. D. Boral Capital currently has a $18.00 target price on the stock.

GeoVax Labs Trading Down 12.6 %

NASDAQ:GOVX opened at $1.11 on Friday. The stock’s 50-day moving average is $1.67 and its 200-day moving average is $2.13. GeoVax Labs has a 1-year low of $1.09 and a 1-year high of $11.18. The stock has a market cap of $10.47 million, a P/E ratio of -0.20 and a beta of 3.06.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.49. The company had revenue of $3.00 million during the quarter, compared to analyst estimates of $2.38 million. As a group, equities analysts forecast that GeoVax Labs will post -4.49 EPS for the current year.

Institutional Investors Weigh In On GeoVax Labs

Several large investors have recently modified their holdings of the company. Virtu Financial LLC acquired a new position in GeoVax Labs in the third quarter valued at $97,000. Citadel Advisors LLC acquired a new stake in shares of GeoVax Labs during the 4th quarter worth approximately $104,000. Northern Trust Corp bought a new stake in GeoVax Labs in the fourth quarter valued at $29,000. Finally, Geode Capital Management LLC boosted its position in shares of GeoVax Labs by 59.0% during the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock worth $223,000 after purchasing an additional 33,440 shares in the last quarter. 6.09% of the stock is currently owned by institutional investors and hedge funds.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.